Nicole Prutsch
Overview
Explore the profile of Nicole Prutsch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
419
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Suske T, Sorger H, Manhart G, Ruge F, Prutsch N, Zimmerman M, et al.
J Clin Invest
. 2024 Apr;
134(8).
PMID: 38618957
T cell acute lymphoblastic leukemia (T-ALL) is an aggressive immature T cell cancer. Mutations in IL7R have been analyzed genetically, but downstream effector functions such as STAT5A and STAT5B hyperactivation...
2.
Prutsch N, He S, Berezovskaya A, Durbin A, Dharia N, Maher K, et al.
Cell Rep Med
. 2024 Mar;
5(3):101472.
PMID: 38508140
Anaplastic large cell lymphoma (ALCL) is an aggressive, CD30 T cell lymphoma of children and adults. ALK fusion transcripts or mutations in the JAK-STAT pathway are observed in most ALCL...
3.
Jing C, Prutsch N, He S, Zimmerman M, Landesman Y, Look A
Br J Haematol
. 2023 Feb;
201(3):489-501.
PMID: 36746437
TET2 inactivating mutations serve as initiating genetic lesions in the transformation of haematopoietic stem and progenitor cells (HSPCs). In this study, we analysed known drugs in zebrafish embryos for their...
4.
Morita K, He S, Nowak R, Wang J, Zimmerman M, Fu C, et al.
Cell
. 2022 Aug;
185(16):3058.
PMID: 35931023
No abstract available.
5.
Liang H, Costanza M, Prutsch N, Zimmerman M, Gurnhofer E, Montes-Mojarro I, et al.
Nat Commun
. 2021 Sep;
12(1):5577.
PMID: 34552066
Anaplastic large cell lymphoma (ALCL), an aggressive CD30-positive T-cell lymphoma, comprises systemic anaplastic lymphoma kinase (ALK)-positive, and ALK-negative, primary cutaneous and breast implant-associated ALCL. Prognosis of some ALCL subgroups is...
6.
Prutsch N, Gurnhofer E, Suske T, Liang H, Schlederer M, Roos S, et al.
Leukemia
. 2020 Jul;
34(11):3105.
PMID: 32665700
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
7.
Jing C, Fu C, Prutsch N, Wang M, He S, Look A
Leukemia
. 2020 Jun;
34(11):2992-3006.
PMID: 32572188
Inactivating mutations in TET2 serve as an initiating genetic lesion in the transformation of hematopoietic stem and progenitor cells (HSPCs). Thus, effective therapy for this subset of patients would ideally...
8.
Morita K, He S, Nowak R, Wang J, Zimmerman M, Fu C, et al.
Cell
. 2020 Apr;
181(3):702-715.e20.
PMID: 32315619
Protein phosphatase 2A (PP2A) enzymes can suppress tumors, but they are often inactivated in human cancers overexpressing inhibitory proteins. Here, we identify a class of small-molecule iHAPs (improved heterocyclic activators...
9.
Prutsch N, Gurnhofer E, Suske T, Liang H, Schlederer M, Roos S, et al.
Leukemia
. 2018 Aug;
33(3):696-709.
PMID: 30131584
TYK2 is a member of the JAK family of tyrosine kinases that is involved in chromosomal translocation-induced fusion proteins found in anaplastic large cell lymphomas (ALCL) that lack rearrangements activating...
10.
Snijder B, Vladimer G, Krall N, Miura K, Schmolke A, Kornauth C, et al.
Lancet Haematol
. 2017 Nov;
4(12):e595-e606.
PMID: 29153976
Background: Patients with refractory or relapsed haematological malignancies have few treatment options and short survival times. Identification of effective therapies with genomic-based precision medicine is hampered by intratumour heterogeneity and...